These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12966161)

  • 1. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
    Moss KG; Toner GC; Cherrington JM; Mendel DB; Laird AD
    J Pharmacol Exp Ther; 2003 Nov; 307(2):476-80. PubMed ID: 12966161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
    Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
    Sun L; Liang C; Shirazian S; Zhou Y; Miller T; Cui J; Fukuda JY; Chu JY; Nematalla A; Wang X; Chen H; Sistla A; Luu TC; Tang F; Wei J; Tang C
    J Med Chem; 2003 Mar; 46(7):1116-9. PubMed ID: 12646019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
    Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit.
    Botchkareva NV; Khlgatian M; Longley BJ; Botchkarev VA; Gilchrest BA
    FASEB J; 2001 Mar; 15(3):645-58. PubMed ID: 11259383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair.
    Hachiya A; Sriwiriyanont P; Kobayashi T; Nagasawa A; Yoshida H; Ohuchi A; Kitahara T; Visscher MO; Takema Y; Tsuboi R; Boissy RE
    J Pathol; 2009 May; 218(1):30-9. PubMed ID: 19214986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
    Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor.
    Routhouska S; Gilliam AC; Mirmirani P
    Arch Dermatol; 2006 Nov; 142(11):1477-9. PubMed ID: 17116839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
    Morimoto AM; Tan N; West K; McArthur G; Toner GC; Manning WC; Smolich BD; Cherrington JM
    Oncogene; 2004 Feb; 23(8):1618-26. PubMed ID: 14985702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
    Schueneman AJ; Himmelfarb E; Geng L; Tan J; Donnelly E; Mendel D; McMahon G; Hallahan DE
    Cancer Res; 2003 Jul; 63(14):4009-16. PubMed ID: 12873999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
    Abrams TJ; Murray LJ; Pesenti E; Holway VW; Colombo T; Lee LB; Cherrington JM; Pryer NK
    Mol Cancer Ther; 2003 Oct; 2(10):1011-21. PubMed ID: 14578466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of Kit signaling for melanocyte stem cells against radiation-induced genotoxic stress.
    Aoki H; Hara A; Motohashi T; Kunisada T
    J Invest Dermatol; 2011 Sep; 131(9):1906-15. PubMed ID: 21633369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
    Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
    Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis.
    Kumano K; Masuda S; Sata M; Saito T; Lee SY; Sakata-Yanagimoto M; Tomita T; Iwatsubo T; Natsugari H; Kurokawa M; Ogawa S; Chiba S
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):70-8. PubMed ID: 18353145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs.
    Na YJ; Baek HS; Ahn SM; Shin HJ; Chang IS; Hwang JS
    Biochem Pharmacol; 2007 Sep; 74(5):780-6. PubMed ID: 17658483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation.
    Park HY; Lee J; González S; Middelkamp-Hup MA; Kapasi S; Peterson S; Gilchrest BA
    J Invest Dermatol; 2004 Jan; 122(1):159-66. PubMed ID: 14962104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
    Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
    Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCF/c-kit signaling is required in 12-O-tetradecanoylphorbol-13-acetate-induced migration and differentiation of hair follicle melanocytes for epidermal pigmentation.
    Qiu W; Yang K; Lei M; Yan H; Tang H; Bai X; Yang G; Lian X; Wu J
    Cell Tissue Res; 2015 May; 360(2):333-46. PubMed ID: 25727244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U; Christofferson R
    Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.